Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation
Abstract Insulin resistance is a major contributor to the pathogenesis of several human diseases, including type 2 diabetes, hypertension, and hyperlipidemia. Notably, insulin resistance and hypertension share common abnormalities, including increased oxidative stress, inflammation, and organelle dy...
Main Authors: | Jin Wook Lee, Hyun-Oh Gu, Yunshin Jung, YunJae Jung, Seung-Yong Seo, Jeong-Hee Hong, In-Sun Hong, Dae Ho Lee, Ok-Hee Kim, Byung-Chul Oh |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-05-01
|
Series: | Experimental and Molecular Medicine |
Online Access: | https://doi.org/10.1038/s12276-023-00982-6 |
Similar Items
-
Cerebroprotective effects of angiotensin II receptor blockers: candesartan focus
by: O. D. Ostroumova, et al.
Published: (2018-09-01) -
Differential clinical profile of candesartan compared to other angiotensin receptor blockers
by: Zimlichman R
Published: (2011-12-01) -
Angiotensin II receptor blockers in the treatment of arterial hypertension in patients with concomitant pathology: focus on candesartan
by: D I Trukhan
Published: (2014-09-01) -
Abilities of candesartan and other AT receptor blockers to impair angiotensin II-induced AT receptor activation after wash-out
by: Yoshihiro Kiya, et al.
Published: (2012-03-01) -
Effect of angiotensin II receptor blockers, candesartan, on osteoprotegerin level in hypertensive patients: Link between bone and RAAS
by: H Oz, et al.
Published: (2015-09-01)